HCN Oncology Essentials: Multiple Myeloma | Debate: Marrow vs. Peripheral Blood | Soft Tissue SarcomaSeptember 07, 2021 | Oncology Hematology Marrow or Peripheral Blood for Allogeneic Transplant: Are We Ignoring the Data? Despite peripheral blood making up 80% of all of hematopoietic cell transplants, there are similar rates of overall survival, disease-free survival, and transplant-related mortality when comparing marrow and peripheral blood as graft sources. Chronic graft-versus-host disease (GVHD) and cytokine release syndrome (CRS) are more significant in those who received peripheral blood, yet the standard of care hasn’t changed. Here, two doctors reflect on the debate. Read full article Geriatrics Treatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma Reference Source: JAMA Network OpenDesign: Retrospective study of 8,953 patients from the National Cancer Database; compared the use of definitive treatment between 2004 and 2014 of 1,280 young adults (YAs, aged 18-39 years); 3,937 patients aged 40-64 years; and 3,756 patients age 65+.Results: Amputation – 8.1% (YAs), 5.5% (40-64), 5.3% (65+). Chemotherapy – 39.4% (YAs), 29.5% (40-64), 9.3% (65+). Radiation – 59.3% (YAs), 69.1% (40-64), 63.4% (65+). Unique to young adults, clinical stage II disease vs. stage I disease and positive surgical margins were not associated with the use of radiation. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS